NAD+

Home › Research › NAD+

View NAD+ in the AxYn range →

Snapshot

Chemistry and make-up

This is the single most important fact on this page: NAD+ is not a peptide. It is nicotinamide adenine dinucleotide, a coenzyme (a small-molecule dinucleotide) built from two nucleotides (one carrying nicotinamide, one carrying adenine) joined through a pyrophosphate (two phosphate) bridge and two ribose sugars. There are no amino acids, no peptide bonds, and no “sequence”. It is filed in this brain only because AxYn sells it commercially next to mitochondrial/longevity peptides, not because it belongs to the same chemical class.

Because it is a phosphorylated dinucleotide rather than a peptide, its chemistry and QC are different. NAD+ is hygroscopic and hydrolytically less stable than many lyophilised peptides; it is sensitive to moisture, heat and pH, and can degrade to nicotinamide and ADP-ribose. Identity and purity are confirmed by HPLC and UV (characteristic ~260 nm absorbance) and mass spec, not by peptide-style sequence confirmation. So a NAD+ CoA should look different from a peptide CoA: expect HPLC purity, water content, and confirmation it is the oxidised (NAD+) form rather than degraded to nicotinamide. Verify formula/MW against PubChem CID 5892 (C21H27N7O14P2, ~663.4 g/mol), matching the brief.

What it is studied for (evidence)

• Mechanism (well established [A]): NAD+ is a genuine, textbook central cofactor. It shuttles electrons in metabolism as the NAD+/NADH couple and is the required substrate for sirtuins, PARPs (DNA repair) and CD38. Cellular NAD+ falls with age. This part is not controversial.
• What the human longevity/metabolic evidence actually shows (mixed [A]): most human trials study precursors (NMN, NR) rather than NAD+ itself. Oral NR/NMN reliably raise NAD+ biomarkers in humans and are generally well tolerated, but effects on hard outcomes (insulin sensitivity, blood pressure, artery stiffness, performance) are modest and inconsistent, and no trial has shown lifespan extension in humans (NR in older adults, PMC5876407; NMN safety, PMC9400576; systematic review 2026, ScienceDirect) [A].
• NAD+ itself vs precursors: direct NAD+ (including IV NAD+ drips marketed by wellness clinics) has weaker human evidence than the precursors, because intact NAD+ is largely broken down before cells take it up; much of a dose is thought to be metabolised to precursors first. Efficacy claims for IV NAD+ specifically are poorly supported (NPR review 2026) [A/D].
• Marketing claims vs data: wellness marketing presents NAD+ as an anti-ageing, energy, cognition and “cellular repair” cure-all. The honest reading: raising NAD+ has clear biological activity but unproven clinical anti-ageing benefit in humans. Biomarker change is not the same as living longer or better.
• Human clinical status: no approval as an anti-ageing therapy anywhere. NAD+ and its precursors are sold as supplements/research materials, not licensed medicines for longevity.

Handling, format and stability

Usually supplied as a lyophilised powder (free acid or disodium salt) for research reconstitution only (no dosing guidance here). It is more moisture- and heat-sensitive than typical peptides and prone to hydrolysis, so cold, dry, dark storage matters and reconstituted solution is short-lived. A degraded batch drifts toward nicotinamide/ADP-ribose, which a proper HPLC CoA should catch. Note this different stability profile when it is stored or shipped alongside peptides.

Regulatory and trade status

• UK/EU: NAD+ and precursors sit in an awkward supplement/novel-food/RUO space rather than being licensed medicines. Keep listings research-use and avoid disease or anti-ageing treatment claims, which could pull it into medicines regulation.
• US: not an FDA-approved drug for longevity. Note the FDA has taken enforcement positions on NMN’s supplement status; NAD+ itself is commonly sold as a research chemical / compounding ingredient. IV NAD+ is offered by clinics but is not an approved therapy.
• WADA: NAD+ and its precursors (NMN, NR) are not named on the 2026 Prohibited List and are not banned in sport (unlike MOTS-c, which is prohibited under S4.4.1). As a natural, endogenous cofactor rather than a pharmacological performance agent, it is not caught by the S0 non-approved-substance catch-all either (WADA 2026 Prohibited List) [B].
• Customs: lower scrutiny than controlled peptides, but identity (NAD+ vs precursor vs degraded material) is the trade risk.

Sources

• [A] Chronic NR supplementation raises NAD+ in older adults (PMC5876407) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/
• [A] NMN oral safety in healthy adults (PMC9400576) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400576/
• [A] NIAGEN (NR chloride) long-term RCT, overweight adults (PMC6611812) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611812/
• [A] NAD+ for anti-ageing/wellness, PRISMA systematic review 2026 (ScienceDirect) — https://www.sciencedirect.com/science/article/pii/S1568163726000498
• [A] NMN vs NR mechanisms/clinical comparison, *Food Frontiers* 2025 — https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511
• [A/D] NPR review of NAD+ infusions/supplements and the evidence (2026) — https://www.npr.org/2026/05/11/nx-s1-5813664/nad-infusions-supplements-longevity-science
• [B] PubChem CID 5892 (NAD+), CAS 53-84-9
• [D] Wellness/clinic pages promoting IV NAD+ — commercial; claims outrun the data.

Plain summary

NAD+ (nicotinamide adenine dinucleotide) is not a peptide. It is a small coenzyme with no amino acid sequence, sold next to peptides only for commercial/longevity positioning, and it is more moisture- and heat-sensitive than a typical lyophilised peptide. It is a genuine, essential cellular cofactor whose levels fall with age, and precursors like NMN and NR reliably raise NAD+ markers in people, but human evidence for actual anti-ageing or metabolic benefit is modest and inconsistent, and IV NAD+ specifically is weakly supported. Sell it honestly: real biology, unproven longevity payoff, and make sure customers do not assume it is a peptide or confuse NAD+ with NMN/NR.

For laboratory and research use only (RUO). Not for human or veterinary use, not for consumption, and not a medicine. Information is a research summary, not medical advice, and contains no dosing guidance.

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine. This is a research summary, not medical advice, and contains no dosing guidance.